RMTI - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Rockwell Medical 2020 Second Quarter Results Call. [Operator Instructions].

As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Claudia Styslinger, Investor Relations. Please go ahead.

Claudia Styslinger

Second Earnings Medical's Call. Rockwell to Quarter Results XXXX Welcome the of representative This Styslinger Partners, Investor is Claudia Argo Relations Medical. for Rockwell

line. Joining is Marketing; Chief who joining and and Principal today's Medical on McGarry, Vice President Officer, Officer; Rockwell Officer; on Corporate Dr. for Paul Chole, us from Controller and Tim of Ellison, Executive and be Dr. call President will Vice Accounting the also President, Russell Q&A Chief me are Medical Marc Hoffman,

we continue, to forward-looking we within federal Before could, predict, wanted intention will Triferic discuss plan, AVNU. expressions not statements or statements. project, Words or the the to potential, matters I similar as that intend Triferic forward-looking certain intent, Medical's Dialysate but begin, expectations note will, are of to, including, may such current statements estimate, securities Rockwell belief commercialize limited should, or constitute regarding laws, meaning might, forecast, and anticipate, may, believe, expect,

would our different. these upon based be and and reasonable, in available to could medical such of limitation, are beyond forward-looking should to to those of subject and as information Rockwell result events many alter on any Rockwell Medical's results forward-looking and like for expressly of set At Rockwell any new rebroadcast these to inherent you on Russell? Russell Actual materially on web except to Rockwell Ellison. placed medical are page. accessed Relations undue based Chief Medical's call statements, various which required or to Dr. call current control be estimates on I uncertainties, not is forward-looking law. call conference are on are as otherwise, disclaims web this are the subject reliance which forth also statements, uncertainty. page. same future statements XXXX, the assumptions any the change. risks and recorded including, and by obligation be This XX, without Accordingly, SEC place can filings, to not believes accessed undue statements Investor this us date on Rockwell While over subject should August which can reliance time, being forward-looking Medical's information, release These are update or audio a Officer, conference This whether on be statements. Executive turn

Russell Ellison

to areas. afternoon, everyone, product, other the mechanism on inflammation. has our attributes analysis. updates transformational iron platform Progress any citrate, our particularly preparation of bioavailable this to platform. By pyrophosphate your immediately commercial delivers Good our Claudia. Q&A. FPC up of in virtue second time that from first XXX% our AVNU, of corporate again potentially we thank CEO unimpeded including opportunity the call, thereby I've to light way said particularly our the for leading is for real-world about the And commercialization community, opportunity say managed and believe financials, The our indications. opportunities indications pertinent FDA Triferic action, for new launch review and FPC in of excited iron of providers, for FPC to of is you, this meaningful see platform, to data Triferic our of or I'm the FPC, I other technology product product patients It for our market and by potential on the ferric COVID-XX take our unlike product, to transforming today. and platform, the My today's the our Thank first benefits FPC pharmacoeconomic I'd we'll commitment approved globe like hospitalization a is Triferic care and today. shareholder. then for X approved it data potential charge progress deficiency you I before, patients the patients across open and actualize will of address to ongoing Dialysate, retrospective the iron On therapeutic hemodialysis our health the pandemic. in from deliver technology clinical and on updated for multiple as

The first ability managed the is transform the patients. way is anemia for to hemodialysis

XX hemodialysis. program Medical change build hemodialysis to second to the The dialysis underpinned expected anticipate in clinical come with on the information help anemia provide our to of XX anemia are we We program. in we treat additional treatment expect by to capabilities be next development setting relevant is call important including the market that to plan year, position the opportunity citrate Rockwell which from additional impact end, pleased of that because data. about medical Triferic Triferic from I'm the and continue needs. in next patients. and medical, this of to hemodialysis generate HIF-PHI of medical the the pharmacoeconomic Triferic FPC and the months, To alongside is pyrophosphate the We data, to setting, the physiologic to for reliable data to Triferic. on in ferric that HIF-PHIs sharing present the is strategically or of which in we continue Also hospitalizations today. an anticipated To introduction other a innovations, HIF-PHIs accelerate conditions data our clinical adoption management through of to and is establishing to leverage scientific molecule some hemodialysis decision-making pharmacoeconomic unmet real-world

that of potential be to company, areas that make of setting the dialysis concentrates opportunities setting. community for states. way deficiency Underpinning managed development a our outside a moments, disease therapeutic is dialysis conditions leading hemodialysis the the iron commitment has transform with I other in variety the molecule value to hemodialysis the the I'll platform medical is for new the In believe treat unmet to the FPC few business. attractive and in addressing attributes the the Regarding same needs creation clinical potential the FPC the subsequent our

in #X which products generate these the annual than in we we revenue. supplier the million of reminder, $XX more U.S., in a As are

forward, While to the profit way growth the Triferic. with paving and concentrates the business allows discussions customers Triferic develop industry is in our the relationships business going we and for customers key for harvest with are on is us clearly and having driver

the patients differentiated action, and mechanism hemoglobin iron has commitment patients immediately is challenges COVID-XX continues part to to is the XXXX. AVNU I'm innovative a in by and for dialysis quarter has to of faces unique patients of is to only other maintain It of treatment. receive because ferritin are health hemodialysis the increasing indicated system. unique multiple maintains The the the Triferic to literally each the The the Furthermore, indications. many without care treatment to iron access way And Triferic, our that potential replace can COVID-XX hemodialysis company expanding formulation dialysis our and impacts of and benefit U.S. X of and carrying pandemic. delivers dialysis our in FDA-approved are times hemoglobin kidney it fourth which acute therapy in patients' lives options the on and during comorbidities in which failure, safety administrative and unique we patients not including excellent already now approved. is iron formulations the an with in placebo supporting a overload of to comparable development that patients role and week. toxicity. with profile Triferic May associated to one dependent for our has Triferic patients in respond health the the FDA introduce they We and of a put both are clinics. greater AVNU this therapeutic levels providers have our plan that clinicians. Triferic in X XXXX launched of dialysis organ industry launch downstream further provides Triferic the IV failure, quite proud Triferic on times which United quarter plan innovative care new formulation, it States to enhances we We in the multiple and At absolutely be platform stress in outpatient with AVNU, and XXXX. like this, Triferic of critical. fourth Dialysate,

the to seen for disruption us our or of returns the to that either middle new predict am have and are supply we share of crisis, the no concentrate still to in when to it's Triferic. I While for the timing chain pleased normal, we hard a world

because working educators, and to medical nurse of to we dialysis our access of focus nature on by impacted ability restricted our clinics representatives have Triferic in continue This fragile efforts though significant paused sales has to to managing the facilities addition, crisis. have any and possible. patients, our they change virtually promotion the of been educations nonessential In the continue workers, including for protocols where and

further to visits adverse geographies U.S. have review However, we where subject clinic to safe, any started steps in-person that in taken to have slowly certain developments. reopen, careful

the are regulatory We on lines, potential in time Triferic outbreak impact development Dialysate clinical the closely Chile, and globe lines the our India, evaluating approved. also COVID-XX in where on particularly of time recently commercialization the was China and across

I'd to make through applaud particular, of the In on of that with Finally, crisis. extraordinary work working we the And distribution and industry face life-saving I'm essential and the workers their front dialysis clinics all patients our to of ensure efforts efforts in the to those lines therapies. like receive of on and employees sure following are industry come the this commitment every patients. dialysis in manufacturing who to the our day standing proud to

net the second were quarter. the June sales of XXXX. million sales million $XX.X the and some to Triferic $X.X XX, for X turning X of Net Now $X.X million, highlights ended months and were

the more a approved annualized an compared clinics For during adoption clinics, quarter XXXX. And signed with An X with on Triferic converted additional patients QX X,XXX affiliated We QX. representing were increase all in we we and in subsequently, treatments. QX contracted than trained MDO June. XX in therapy, Dialysate, contracted XXX,XXX clinics contracts clinics additional for with to XX% ended nearly

Triferic. is the of small made organization, impact to metrics or disease Our And additional Allen a represent to additional second appoint in provide his combined make policy quarter. Tim of program, organization and programs dialysis our and our will in active adding data Dr. will his Dialysate Directors. seek and Triferic in with executive expertise, the we valuable the independent the him details progress regulatory We at as of large medium Nissenson expanding authority clinics call. real-world thrilled expand clinical, Allen kidney on and evaluation committed a we public renowned later adviser launch dialysis to experience XX a reach reach and were clinic. the senior Board for

Rockwell saw Dialysate discuss regulatory second commercial the Medical, X of Triferic the metrics approval Health AVNU in Finally, to for Triferic and hand call new regulatory Tim? over the plan. Chile. to Canada and quarter milestones the AVNU launch With of the that, I'll acceptance important the submission Chole by drug Tim of Triferic

Tim Chole

progress important the Triferic Dialysate, the make Russell. In pandemic. COVID-XX commercialization to in the quarter, Thanks, challenges second of we continued despite the of

as end first Russell contracted we in attributable had was with increase XXX,XXX that at annualized quarter. of the therapy than clinics evaluation the XX-day contracts signing of their So June, The to had mentioned, commercial the more X,XXX nearly patients started on programs treatments. representing

high XXXX. evaluation lower-than-expected the majority with rate results overall We to trained contracts with primarily June. quarter, our and new Triferic within person in additional approved from have In see a dialysis subsequently the Triferic in participants an was restrictions continued of on as clinics signed substantially with adopt The in contracted dialysis X to An to for success to own no-cost June we Dialysate. positive staff. levied and with all affiliated field growth sales as in clinics due clinics visits of patients approach XX, in customers. MDO converted were the the adoption QX clinics second their And quarter, XX see program transition paying Triferic

in a we clinical the new of training with results XX virtual evaluation geographies, track in during to X on evaluations active period. contracts. and COVID-XX clinics certain participated sales we previous the However, us programs. back by saw in are to close our up clinics took pleased now and the produced period. reengage under allow we which quarter they have get The the the has clinics U.S. restrictions with quarter second tactics number added in total our clinics relaxing with for while number engagement versus to of on programs,and to a due clinics for launch XX since delaying XX. and planned more the Triferic Triferic Dialysate allowed Late of quarters decrease clinics training a in-person teams The contract sample was a quarter, focused been our educator have the programs decrease to through leveraging nurse programs Evaluation product complete crisis. X-month directly full managing

to presented is of experience clear challenges until by to Triferic, our equipped while programs U.S. clinics contracts. with such tools evidenced company, tend to a has gain industry, And from with steady customers geographies continue rate COVID-XX to throughout our to the product, field majority evaluation who conversion have Our allowing as with that XX% we force our our time reopen, virtually observation commercial to face-to-face commercial date stay more significant visits. when including with companies the communicate

personnel We see business. adoption expect of evaluation process high Triferic touch, field support This begins the yields the sales and for best COVID-XX U.S. states hands-on and reopen approach to important a high of results. reacceleration to the Triferic and a resolve as is for our pandemic particularly more by since

Triferic. I'll AVNU, Next, to turn of IV formulation Triferic our

replace providing as Triferic Triferic and therapeutic delivery only hemodialysis administer and hemoglobin dependent to bicarbonate maintain centers being by the platform FDA-approved of in patients to Triferic AVNU Triferic administration in March, used. adult by AVNU using regardless to is approval patients greater indicated Triferic chronic joins hemodialysis dry allows the disease. Dialysate administration designed a for technology. AVNU the FDA is innovative for of the our clinics. patients is intravenous to products therapy enhances with And the mode The options kidney hemodialysis with appropriate adult With thus dialysis iron in where of bicarbonate cases expanding more to patients clinic access Triferic

outreach to Triferic. launch to the commercial it for launch our have in have awareness we're we their the increase product to already access quarter We're in the bicarbonate that Applying year. adding parallel, adopt so ongoing. to label the At preparing same customers past access expressed the that samples brand with dry out later Dialysate can to and our contracts learnings due stage and Currently, evaluation later programs name. prospective this for have quarter to sample the bicarbonate Regarding Triferic been started to customers to the communications Triferic will this will set product and final programs second clinics Dialysate, impending for customers that the we signal of marketing Triferic launch customers the manufacturing is expect from Triferic our of initiate reaching with includes time, established availability FDA-approved launch systems educational to in and the with agreements, who technology. commercial In plan Participating who in Triferic of we are to those AVNU, the have prospective but in have both launch. engaging of third AVNU dialysis to use patients unable dry to their also utilize organizations for free of and commercial we advance treat measure results. interest integrated

the and with help parallel, contracts onboard Triferic Accordingly, period, to so clinics evaluate to commercial we for negotiate the their we programs. the the evaluation them we education the will begin assuring evaluation to point customers while of sales in early training quarter the also in completion of proper reached them evaluation the commence plan the to complete. AVNU reviews ready targeted adoption as as fourth are XXXX once we of clinics clinics impact During commercial schedule staff. that clinic paying with the of Triferic, lab In regular is

I'll broadly most. in need transformational will for patients this plans to But back commercial it that believe call reimbursed prevalent Russell? that of continue program. make update coming provide Medicaid reimbursement, AVNU therapy enables detail We terms margin who providing be Triferic the forward patients an is the been we established is by ESRD for progress to look Medicare still our accessible bundle gross cost to that, to on and to for importantly, Triferic us Russell data that attractive the anticipate months. the our more ensuring launch and turn an AVNU the has we payment while CMS real-world on to patients. structure In With within increasingly

Russell Ellison

important was dialysis Dialysate measures We part to this Renal time last that of other we States mortality Triferic period, with System, accessed use And analyzed presented on and the our program quarterly Tim. hospitalization of year center Disease call. sample Thanks, centers as we USRDS, in compare and the or which compared all the same the clinic first in during the XXXX. United

in As this slide in-patient very other infectious you these in parameters substantially and per changed the in-patient while infectious days, even as during from can dialysis that death, hospitalizations did period. little taken centers hospitalization, see center, U.S. year declined all days together,

once real-world iron We will EPO each the add completed site our use, data analysis of And a centers and start we have use, to IV program. continued to new of use. is year hemoglobin

have have the addition, an commenced of this In end and we expect USRDS to clinics the database these using results of analysis towards multiple year.

indications. Now turning to new our

an payers currently a through benefit. the FDA infusion end Type million discussion, pending with safely only as an and iron total to a due hypersensitivity be for We with In cost subset leading As requirements these attractive I And to initiated home. anemia in-office iron We this there is With $XXX to significant XX%. of mentioned favorable, studies home office completed that setting at patients of is for that completed on we way a This earlier hemodialysis hospital deficiency high for and whereas years. drugs business nutrients. program through regimen million infusion months, market covered be million. that and FPC clinical these that anemia C experiencing development to we've iron of payers, area IV largely $X year pricing indications of factors deficiency meeting Currently, where for to outside program. because managed. creation we administered relatively estimated I needs for drugs value economics home greater we in a X.X of met be estimate new or of million past while XX costly evaluating top been an cost therapy XXXX likely believe the patients risk infusion, for in and considerations, such iron administration and is in is to have and of to Phase the there the as this believe as treat of incidence be opportunities. call, reduce B multiple million visits the have at in home and this commercial ergonomics, the program discuss can of low. identified new iron IV months, FPC believe estimate patients FPC priority for IV to for products, to in XXX,XXX part FPC as market estimate could FPC want the an deficiency development receiving is specific deficiency Phase the million few platform potential be will by $X.X patients XX transform nutrients be the the could $X cost access important FPC infusion iron that the through approximately potential could is of substantial the be be X through analysis by platform to we home patients opportunities our The or this II estimate Based a are to indications. XXXX XXXX. in as opportunity the large III to and market to with coverage opportunity a the Medicare and/or growth than currently intend $X.X approximately treated we from of be We is X XX% in In our

outpatient The function patients patients. consideration benefit failure is demonstrated failure FPC acute of older second Studies heart to priority consistently with in cardiac setting. in forms iron improve in hospitalized have under heart congestive the parenteral meaningful

of liver a the produce slow However, hospital from be products, in to to the setting. release iron the with is these benefit too likely

clinical of in function And enable of cardiac their bioenergetics FPC goal call potential proof-of-concept improvement detail the you provide their and stay clinical commercial clinical hold conference a III because Phase However, and could details function would more thought and/or such and Rockwell join with patients and turn for near will Phase quarter depth call The of program. call, cardiac September second feasibility to the readmission. will indication, details on on the that future. will accessing estimate reducing length the in on a study the costs. Paul more encourage a examining conference program. provide iron, call problems new it the and that, relevant on on with I as and bioavailability our indications webcast XX-day management associated over associated improve We hospitalized the information McGarry we'll II each The programs. new to clinical With of financials. to provides a Paul? XXth We the along immediate of the rationale in leaders it review team, in of an clinical include

Paul McGarry

Russell. Thanks,

financial the equity facility at million, XXX,XXX our XX, investments June balance X stock our of now in results. in $X release of can quarter. quarter fulsome of million afternoon I through highlighting as A more our XX, of activities Turning was net second million sale results a our results. the I'd our and market complete offering by of We sale was start XXXX. by understanding the months XX-Q approximately issuance quarter proceeds of the accessed operating on like for disclosures available we end as would encourage this And filing March detailed for costs. description well both of of ended equivalents our ended the XXXX. with cash, to $XX.X read for the cash as used The sheet strengthened to our for the investors issued the quarter. common for be of liquidity compared million press to $XX position second shares $XX.X our Cash more to strong

under facility. have We this remaining $XX.X million approximately

a increase statement. sales was of million during million by profit second cost quarter due as X.X% our of primarily the offset second constant. to the increased compared international from million due the sales of the in of demand $X.X expenses. of G&A approximately which of expenses, $XX now million, in to XXXX. an $XX.X quarter marketing marketing decline expenses, and sales have in increase XXXX in in a President with XXXX. a consulting $X.X a to remained R&D investments year-over-year in XXXX reduction sales million sales selling were been losses of of investments million our primarily was to from gross and fees of increase million million COVID-XX expenses and our the second by were marketing of quarter in second the an settled sales net in reduction the expenses to of of of former launch million of sales Cost offset Gross and The profit for $X.X second $X.X of largely an included quarter is resulting Dialysate to $XX.X by licensing quarter due in million, $XX.X incentive for The for for and costs. our million and second million $X.X reduction million litigation $X.X the the the a increase by to to ongoing of gross The income to to XXXX The loss $X.X infrastructure operating labor quarter XXXX. the second lower quarter driven sales result mainly material were support a partially $XX.X increase driven compared in $X.X profit compared reduction sustain the resulting XXXX Turning in compensation of of our $X.X a Net in and costs increase in to sales in compared continued net during improved for of million in made legal primarily products. quarter were dialysis was second we was XXXX, The pandemic. G&A dialysis primarily to in costs upfront product XXXX the for and net the operating second quarter expenses from various our sales our products, improvement Operating a the by and Triferic. sales concentrates decline quarter Triferic second reduction of the in quarter matters associated decline CEO; Triferic approximately concentrate increased a of related XXXX XXXX. that second an the of increased

on to the global to quarter investments Triferic, Finally, included to and platform data are the we've medical made earlier make Triferic which and launch decline of medical our our in call. continue generate we and R&D support presented investments including largely this our expenses to and enhance FPC the platform, costs of the we made upfront XXXX platform data the certain in in due support timing development year-over-year during second of to the

basic the of product in expenses development pediatric the in to our development loss research net forward important additional clinical is $X.XX due second Net million international An quarter XXXX company our efforts area business of the diluted that for basic and to $X.X or $XX.X expect of our second for of is trial and to the in the share. increase headcount education Triferic. quarter per going of innovations support do we in see diluted development an value triferic We And for Triferic, international to our A we shareholders. for activities opportunity this, objective future or $X.XX per compared XXXX to was and million and FPC a technology to an medical administration increase loss and of for platform, clinical company additional continuation share as our access markets. increase the to for create significant is to Triferic.

Earlier Pharma Sun the partner, and globe. regulatory for patients. India the to hemodialysis to diligently has XXX,XXX discussions to are Triferic Sun license India support data believe us we meetings the year, Triferic India attractive in with with agreements initiated. regulatory commercialize been Wanbang potentially accelerate a determine regulatory for Triferic generating Sun the and approval. we In having Importantly, into exclusive the are for over a have filing Biopharmaceutical China, are potential around has business continues In some for to with pathway this we authorities help India. follow for entered market to the development a to in supply trial that authorities approval. the with a our we real-world of quarter, initiate rights Triferic we Pharma between Pharma regulatory working second the to

drug filed regulatory and South in continued for With this study hemodialysis year. recent rate will for late in which has to making new we the excited in the Triferic AVNU approval in a in that of in And potential with Canada, commercial America, single a transfer later regulatory of Access for approved remain over towards initiated Dialysate largest in years. to expect China, Triferic we in In distributor. sold We Triferic accepted royalty launch China product opportunity anticipate the received progressing XXX,XXX to XXXX. the meaningfully In in range be We if commercial participate seek our hemodialysis QX and low distribution Health to Triferic on expect patients to We May in in Canada increase Dialysate China. the submission sales. there. or effective decision the Chile an this early our price markets, with Peru these the are Triferic we Triferic both of a world. about rapid mid-XX% market it partner at is QX

benefits are be turn geographies, regulatory approval. Triferic. both partnered. on for potential of and are is with continuing in call and of and discussions studies Triferic these require Russell. call earnings prospective presented the markets markets the other complex accordingly, We for and to our more economic some where real-world some clinical highlight are health leverage I'll due XXXX discussions that facilitate Europe that to the Japan, believe expect pharmacoeconomic observed diligence discussions to we are we to now will with back call data and that in And also inherently the on may this We we of QX partners as already having such Triferic in licensing

Russell Ellison

questions. ask to Operator? open you, call up Thank would With that, to Paul. to the I like others

Operator

And the our first question H.C. comes Selvaraju Instructions]. of line [Operator Wainwright. from from Ram

Blair Cohen

us initial reception been for for Blair the me. evaluation from stage how What you the commercial Ram. are many couple -- programs are And Can the customer you questions for reception This efforts progressing on outreach? the bit AVNU? early on A update is for of is Cohen like the quarter? of little a give how third targeting

Russell Ellison

Thanks, this. Ram. best to you think, Tim, I reply can

Tim Chole

for you question. thank the Yes,

has to third response we So just Initial started AVNU. have September. interest to we that in sample Triferic them past ramped to evaluation good. Customers launch excited formulation officially up actually expressed in Triferic been see have coming. here the is We'll support new in quarter that the in were Again, until we programs had the programs. IV had those inventory enough wait this for

us. that, some year the programs the about And as those evaluation be as of and for so to end be before minimum soon responses amongst date. had and product excited are of good Though, customers XXX certainly customers. sites many starting for we early the enthusiasm interested are is expect that the And a available. have a indication we will to And as product is there targeting evaluations goal in the we

Blair Cohen

Great. Japan in on could Europe, an discussions me. it Okay. partnership provide just for update and you if That's Korea. And

Russell Ellison

Yes, I'll take that.

real-world goes because also Japan. engaged active is, for by ongoing same goes discussions, And Japan, the we're And those the of of and in And for in are pricing Europe, Korea. in regime particularly a partnership issue in the discussions there, So supported our key course, data. markets. pricing but same

Operator

comes line Our the of Brandon Cantor next question Fitzgerald. from from Folkes

Brandon Folkes

progress the question. of It's the Congratulations a all X-part kind on in quarter.

elaborate to very So this found drivers the be just on in can impressive. you I quarter? growth patient of the

think revenue significant it pull-through. sort until as after signed facilities midsize these this you solid or usage signed And to of secondly, Is facilities? conversion part about whole up these those the evaluation how we convert were program contracts a by driven long the growth run the large facilities? small, patient ramp-up from should already just within it take sort just, facilities increased for was within new then the of then of clinic? my of actually these and ends, question had the And or Or rate past second So you contracts? how they saw contracted clinics is that does a

Russell Ellison

Tim? questions. great are Those

Tim Chole

for you questions. Thank the Yes.

ready finished one to to So contract, at to your on when they're purchasing transfer and all Triferic on first customers clinic the time. question, clinics away the over right program Dialysate patients have evaluation in

product. a there patients all ramp-up isn't loop really the is product and So period product. are on with central Because the loop that the received mixed in that the central

a customer's nice and that is the is of contract the there evaluation the once ramp-up is feature isn't Dialysate that's done, signed Triferic So purchasing. a

that clinics new that And of treatments growth finished started had first of XXX,XXX they new that the of in second had the period evaluation the the to milestone majority due really, were our on those contracted is we've the clinics that and annualized were the in quarter patients So had in sort coming board. quarter.

we a today. occurs. a the of growth high So we sense that of programs again, gives how rate for ongoing hopefully, have you And conversion that that expect, evaluation

Operator

Ellison This conclude does to further I'd back the to hand like program Dr. program. today's question-and-answer the for remarks. of any session

Russell Ellison

Well, thank quarterly so support, Thank for appreciate much we again. to attention you I your call. participating your you look and in with communicating you much. all very this and forward

Operator

conclude the Thank for conference. This gentlemen, program. today's and participation you, your in ladies does

disconnect. now day. may You Good

Rockwell Medical (RMTI) 11 Aug 202020 Q2 Earnings call transcript